GRIFOLS SA-ADR (GRFS)
US3984384087 - ADR
Overall GRFS gets a fundamental rating of 4 out of 10. We evaluated GRFS against 588 industry peers in the Biotechnology industry. While GRFS belongs to the best of the industry regarding profitability, there are concerns on its financial health. GRFS is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
GRFS had positive earnings in the past year.
In the past year GRFS had a positive cash flow from operations.
In the past 5 years GRFS has always been profitable.
Of the past 5 years GRFS 4 years had a positive operating cash flow.
1.2 Ratios
GRFS has a Return On Assets of 0.28%. This is amongst the best in the industry. GRFS outperforms 94.19% of its industry peers.
GRFS's Return On Equity of 1.02% is amongst the best of the industry. GRFS outperforms 94.36% of its industry peers.
The Return On Invested Capital of GRFS (2.99%) is better than 95.21% of its industry peers.
The Average Return On Invested Capital over the past 3 years for GRFS is significantly below the industry average of 13.58%.
The 3 year average ROIC (2.86%) for GRFS is below the current ROIC(2.99%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.28% | ||
| ROE | 1.02% | ||
| ROIC | 2.99% |
ROA(3y)0.74%
ROA(5y)2.06%
ROE(3y)2.61%
ROE(5y)6.58%
ROIC(3y)2.86%
ROIC(5y)4.04%
1.3 Margins
The Profit Margin of GRFS (0.90%) is better than 94.53% of its industry peers.
GRFS's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 11.16%, GRFS belongs to the best of the industry, outperforming 95.73% of the companies in the same industry.
In the last couple of years the Operating Margin of GRFS has declined.
The Gross Margin of GRFS (37.84%) is better than 78.80% of its industry peers.
GRFS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.16% | ||
| PM (TTM) | 0.9% | ||
| GM | 37.84% |
OM growth 3Y-15.14%
OM growth 5Y-12.82%
PM growth 3Y-57.33%
PM growth 5Y-41.65%
GM growth 3Y-3.59%
GM growth 5Y-3.69%
2. Health
2.1 Basic Checks
GRFS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
GRFS has about the same amout of shares outstanding than it did 1 year ago.
GRFS has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for GRFS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.11, we must say that GRFS is in the distress zone and has some risk of bankruptcy.
GRFS has a Altman-Z score of 1.11. This is in the better half of the industry: GRFS outperforms 66.15% of its industry peers.
GRFS has a Debt/Equity ratio of 1.58. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.58, GRFS is not doing good in the industry: 81.37% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.11 |
ROIC/WACC0.48
WACC6.21%
2.3 Liquidity
GRFS has a Current Ratio of 2.79. This indicates that GRFS is financially healthy and has no problem in meeting its short term obligations.
GRFS has a worse Current ratio (2.79) than 69.57% of its industry peers.
GRFS has a Quick Ratio of 1.29. This is a normal value and indicates that GRFS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of GRFS (1.29) is worse than 84.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The earnings per share for GRFS have decreased strongly by -71.52% in the last year.
Measured over the past years, GRFS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -36.87% on average per year.
The Revenue has grown by 8.71% in the past year. This is quite good.
Measured over the past years, GRFS shows a small growth in Revenue. The Revenue has been growing by 8.00% on average per year.
EPS 1Y (TTM)-71.52%
EPS 3Y-54.06%
EPS 5Y-36.87%
EPS growth Q2QN/A
Revenue 1Y (TTM)8.71%
Revenue growth 3Y7.27%
Revenue growth 5Y8%
Revenue growth Q2QN/A
3.2 Future
GRFS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.97% yearly.
The Revenue is expected to grow by 6.30% on average over the next years.
EPS Next Y83.85%
EPS Next 2Y55.19%
EPS Next 3Y39.83%
EPS Next 5Y35.97%
Revenue Next Year7.32%
Revenue Next 2Y7.37%
Revenue Next 3Y6.64%
Revenue Next 5Y6.3%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
GRFS is valuated quite expensively with a Price/Earnings ratio of 62.80.
94.87% of the companies in the same industry are more expensive than GRFS, based on the Price/Earnings ratio.
GRFS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.76.
With a Price/Forward Earnings ratio of 6.63, the valuation of GRFS can be described as very cheap.
Based on the Price/Forward Earnings ratio, GRFS is valued cheaply inside the industry as 99.49% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.26, GRFS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.8 | ||
| Fwd PE | 6.63 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GRFS is valued cheaply inside the industry as 97.09% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.44 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GRFS has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as GRFS's earnings are expected to grow with 39.83% in the coming years.
PEG (NY)0.75
PEG (5Y)N/A
EPS Next 2Y55.19%
EPS Next 3Y39.83%
5. Dividend
5.1 Amount
No dividends for GRFS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GRIFOLS SA-ADR
NASDAQ:GRFS (4/19/2024, 7:00:00 PM)
After market: 6.23 -0.05 (-0.8%)6.28
-0.26 (-3.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.26B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.8 | ||
| Fwd PE | 6.63 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.75
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.28% | ||
| ROE | 1.02% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 11.16% | ||
| PM (TTM) | 0.9% | ||
| GM | 37.84% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.58 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.79 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-71.52%
EPS 3Y-54.06%
EPS 5Y
EPS growth Q2Q
EPS Next Y83.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.71%
Revenue growth 3Y7.27%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y